Thu Jan 30, 2014 6:17pm EST
The logo of French drugmaker Sanofi-Aventis is seen on the facade of their headquarters in Paris August 4, 2010.
Credit: Reuters/John Schults
<span id="articleText"/>(Reuters) - French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus.
<span id="midArticle_0"/>The lawsuit, filed in United States District Court for the District of Delaware, was triggered by notification from Lilly last month that it applied with the U.S. Food and Drug Administration (FDA) seeking permission to sell a generic version of Lantus, known chemically as insulin glargine.
<span id="midArticle_1"/>Lilly, in its submission, challenged the validity of several patents on Lantus held by Sanofi.
<span id="midArticle_2"/>Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion.
<span id="midArticle_3"/>Indianapolis-based Lilly had said it will not launch its generic product before the February 2015 expiration of Sanofi's patent on the active ingredient in Lantus.
<span id="midArticle_4"/>But the patent infringement lawsuit triggers an automatic 30-month stay of a generic approval by the FDA, which would keep Lilly's generic off the market until mid-2016.
<span id="midArticle_5"/>Sanford Bernstein analyst Tim Anderson, in a recent research note, said a 30-month delay would raise Sanofi's earnings per share from 2015 through 2020 by about 6 percent and lower Lilly's EPS for the period by about 2 percent.
<span id="midArticle_6"/>A delay in the launch of a generic by Eli Lilly would also give Sanofi more time to switch patients to a new long-acting follow-up product known as U300 once it gains approval before cheap competition for Lantus hits the market.
<span id="midArticle_7"/>(Reporting by Bill Berkrot; Editing by Amanda Kwan)
<span id="midArticle_8"/>
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy
<a name="comments"/>Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
- Tweet<li class="c4"/><li class="linkedIn" tns="no"/>
- Share this
- <span id="googleTag"/>
Credit: Reuters/John Schults
<span id="articleText"/>(Reuters) - French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus.
<span id="midArticle_0"/>The lawsuit, filed in United States District Court for the District of Delaware, was triggered by notification from Lilly last month that it applied with the U.S. Food and Drug Administration (FDA) seeking permission to sell a generic version of Lantus, known chemically as insulin glargine.
<span id="midArticle_1"/>Lilly, in its submission, challenged the validity of several patents on Lantus held by Sanofi.
<span id="midArticle_2"/>Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion.
<span id="midArticle_3"/>Indianapolis-based Lilly had said it will not launch its generic product before the February 2015 expiration of Sanofi's patent on the active ingredient in Lantus.
<span id="midArticle_4"/>But the patent infringement lawsuit triggers an automatic 30-month stay of a generic approval by the FDA, which would keep Lilly's generic off the market until mid-2016.
<span id="midArticle_5"/>Sanford Bernstein analyst Tim Anderson, in a recent research note, said a 30-month delay would raise Sanofi's earnings per share from 2015 through 2020 by about 6 percent and lower Lilly's EPS for the period by about 2 percent.
<span id="midArticle_6"/>A delay in the launch of a generic by Eli Lilly would also give Sanofi more time to switch patients to a new long-acting follow-up product known as U300 once it gains approval before cheap competition for Lantus hits the market.
<span id="midArticle_7"/>(Reporting by Bill Berkrot; Editing by Amanda Kwan)
<span id="midArticle_8"/>
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy
<a name="comments"/>Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
via Smart Health Shop Forum http://ift.tt/MCh3WU
No comments:
Post a Comment